[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Shiran MS, Tan GC, Sabariah AR, Rampal L, Phang KS: p63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions. Med J Malaysia; 2007 Mar;62(1):36-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions.
  • The diagnosis of prostatic carcinoma (Pca) on routine biopsies may be challenging, and to date the commonly used marker to distinguish prostate carcinoma from benign prostatic lesions has been High Molecular Weight-Cytokeratin (HMW-CK).
  • However, the antigen of HMW-CK is susceptible to the effect of formalin fixation and causes frequent loss or patchy staining in the obviously benign glands.
  • More recently, antibodies to p63 have been reported to be more sensitive than HMW-CK for the detection of prostatic basal cells. p63, a homologue of tumour suppressor gene p53, is essential for prostate development and is selectively expressed in the nuclei of basal cells of normal prostate glands.
  • The objective of this study is to compare the sensitivity and specificity of HMW-CK and p63 in distinguishing prostatic carcinomas from benign prostatic lesions, as well as determining their positive predictive values.
  • Seventy-two cases from HUKM (comprising 29 prostatic carcinomas and 43 benign prostatic hyperplasias) were stained for both HMW-CK and p63.
  • The sensitivity of p63 and HMW-CK in identifying basal cells in benign glands was 88.37% and 90.70% respectively.
  • Thus, p63 is a useful complementary basal cell specific stain to HMW-CK, and would be very helpful to practicing pathologists in dealing with difficult cases.
  • [MeSH-major] Keratins. Membrane Proteins. Neoplasms / diagnosis. Neoplasms, Basal Cell / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682568.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


2. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet; 2006 Apr;43(4):289-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.
  • In recent years the use of radiation treatment for benign tumours has increased with the advent of stereotactic delivery and, in particular, single high dose gamma knife therapy.
  • This has been particularly true for benign CNS (central nervous system) tumours such as vestibular schwannoma, meningioma, pituitary adenoma, and haemangioblastoma.
  • While short term follow up in patients with isolated tumours suggests this treatment is safe, there are particular concerns regarding its use in childhood and in tumour predisposing syndromes.
  • We have reviewed the use of radiation treatment in these contexts with particular regard to malignant transformation and new tumour induction.
  • This review indicates that much more caution is warranted regarding the use of radiation treatment for benign tumours in childhood and in tumour prone conditions such as the neurofibromatoses.
  • [MeSH-major] Cell Transformation, Neoplastic. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology
  • [MeSH-minor] Basal Cell Nevus Syndrome / radiotherapy. Humans. Li-Fraumeni Syndrome / radiotherapy. Neurofibromatoses / radiotherapy. Radiotherapy / adverse effects. Retinoblastoma / radiotherapy. Risk Factors. Syndrome. von Hippel-Lindau Disease / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Br J Cancer. 1986 May;53(5):661-71 [3718823.001]
  • [Cites] N Engl J Med. 1987 May 21;316(21):1289-94 [3574400.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] Radiology. 1993 Jun;187(3):843-6 [8497642.001]
  • [Cites] Arch Intern Med. 1996 Sep 9;156(16):1873-8 [8790083.001]
  • [Cites] Int J Radiat Biol. 1996 Aug;70(2):145-50 [8794843.001]
  • [Cites] J Med Genet. 1996 Feb;33(2):120-7 [8929948.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2181-92 [9649131.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Aug;46(4):254-6 [14506573.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):791-6 [14566829.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):378-83 [14672272.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] Ophthalmology. 2004 Jan;111(1):150-3 [14711727.001]
  • [Cites] Lancet. 2004 Jan 31;363(9406):345-51 [15070562.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:65-73 [9782237.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:179-86 [9782249.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1884-93 [10206309.001]
  • [Cites] J Neurosurg. 1999 May;90(5):815-22 [10223445.001]
  • [Cites] Arch Dis Child. 1999 Jan;80(1):1-3 [10325750.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):784-94 [10441587.001]
  • [Cites] Cancer. 1963 Aug;16:1003-14 [14050004.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:195-9 [15662809.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):338-42 [15702831.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Pediatr. 1989 May;114(5):788-92 [2497236.001]
  • [Cites] Surgery. 1991 Oct;110(4):691-5 [1833847.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):998 [10732777.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):667-72 [10793343.001]
  • [Cites] Am J Otol. 2000 May;21(3):364-70 [10821550.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):383-89; discussion 389-90 [10825525.001]
  • [Cites] Br J Neurosurg. 2000 Apr;14(2):93-5 [10889878.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):641-4; discussion 644-5 [10949438.001]
  • [Cites] Cancer Invest. 1999;17(1):56-72 [10999050.001]
  • [Cites] Am J Hum Genet. 1999 Oct;65(4):995-1006 [10486318.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):672-8 [11058888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1381-7 [11121637.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(5):300-4 [11315715.001]
  • [Cites] Int J Cancer. 2001 Aug 20;96(4):238-42 [11474498.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] Radiat Res. 2002 Feb;157(2):158-65 [11835679.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6 [11894972.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Med Genet. 2002 May;39(5):315-22 [12011146.001]
  • [Cites] Arch Dis Child. 2002 Jul;87(1):65-70 [12089128.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):808-17 [12651207.001]
  • [Cites] Lancet. 2003 Mar 29;361(9363):1101-2 [12672316.001]
  • [Cites] Health Phys. 2003 Jul;85(1):47-59 [12852471.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):197-9 [12903592.001]
  • [Cites] Mayo Clin Proc. 2003 Jun;78(6):708-15 [12934780.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5774-83 [12947385.001]
  • [Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]
  • [Cites] Neurochirurgie. 2004 Jun;50(2-3 Pt 2):367-76 [15179291.001]
  • [Cites] JAMA. 1967 Jan 23;199(4):280-1 [4224873.001]
  • [Cites] Am J Surg. 1968 Oct;116(4):518-23 [4300240.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] Ann Intern Med. 1977 Aug;87(2):160-4 [889197.001]
  • [Cites] J Natl Cancer Inst. 1979 Jun;62(6):1347-59 [286106.001]
  • [Cites] Arch Dermatol. 1980 Oct;116(10):1159-63 [7425663.001]
  • [Cites] Arch Pathol Lab Med. 1983 Jun;107(6):293-7 [6687792.001]
  • (PMID = 16155191.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  • [Other-IDs] NLM/ PMC2563223
  •  go-up   go-down


3. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


Advertisement
4. del Carmen López Pacheco M, da Cunha Martins-Costa MF, Zapata AJ, Cherit JD, Gallegos ER: Implementation and analysis of relief patterns of the surface of benign and malignant lesions of the skin by microtopography. Phys Med Biol; 2005 Dec 7;50(23):5535-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implementation and analysis of relief patterns of the surface of benign and malignant lesions of the skin by microtopography.
  • It was observed that when the tumour becomes rougher, more malign will be the lesion.
  • The percentage decreases to 49% (49%, 1:60) in the case of basal cell carcinoma and to 40% in pre-malignant lesions such as melanocytic nevus (40%, 1:150).
  • In benign lesions such as the seborrhoea keratosis only a small increase in roughness was noted (4%, 1:0.72).
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Dermoscopy / methods. Melanoma / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis. Tomography / instrumentation. Tomography / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306650.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Latex
  •  go-up   go-down


5. Karen JK, Gareau DS, Dusza SW, Tudisco M, Rajadhyaksha M, Nehal KS: Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy. Br J Dermatol; 2009 Jun;160(6):1242-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy.
  • OBJECTIVES: To evaluate the sensitivity and specificity of ex vivo real-time imaging with fluorescence confocal mosaicing microscopy, using acridine orange, for the detection of residual basal cell carcinoma (BCC) in Mohs fresh tissue excisions.
  • Very good correlation was observed between confocal mosaics and matched Mohs frozen sections for benign and malignant skin structures, overall tumour burden and location, and identification of all major histological subtypes of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mohs Surgery / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] J Microsc. 2009 Jan;233(1):149-59 [19196421.001]
  • [Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):923-8 [15313861.001]
  • [Cites] J Cell Biol. 1985 Apr;100(4):1309-23 [3920227.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1470-8 [15606734.001]
  • [Cites] J Biomed Opt. 2005 May-Jun;10(3):034009 [16229653.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):305-9 [16433801.001]
  • [Cites] Opt Lett. 2006 Apr 1;31(7):942-4 [16599219.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]
  • [Cites] Opt Lett. 2006 Sep 15;31(18):2756-8 [16936882.001]
  • [Cites] J Biomed Opt. 2007 Jan-Feb;12(1):014005 [17343480.001]
  • [Cites] Appl Opt. 2007 Apr 1;46(10):1843-51 [17356629.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034004 [17614712.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Lasers Surg Med. 2007 Oct;39(9):696-705 [17960751.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1248-55 [17989735.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):152-61 [18460029.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044016 [19021344.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • (PMID = 19416248.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01 EB002715-05; United States / NIBIB NIH HHS / EB / R01EB002715
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS95359; NLM/ PMC2693082
  •  go-up   go-down


6. Garcia L, Nagore E, Llombart B, Sanmartin O, Botella-Estrada R, Requena C, Jorda E, Guillen C: Basal cell carcinoma of the nasolabial fold: an apparently 'benign' tumour that often needs complex surgery. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):926-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the nasolabial fold: an apparently 'benign' tumour that often needs complex surgery.
  • BACKGROUND: Location of the tumour is a well-known prognostic factor for recurrence of basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922939.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


7. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


8. Rafindadi AH, Samaila MO: Histopathologic analysis of epidermal skin tumours and tumour-like lesions in Ahmadu Bello University Teaching Hospital, Zaria. Niger Postgrad Med J; 2006 Dec;13(4):354-6
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic analysis of epidermal skin tumours and tumour-like lesions in Ahmadu Bello University Teaching Hospital, Zaria.
  • OBJECTIVE: A histopathologic analysis of epidermal skin tumours and tumour-like lesions seen between 1991 - 2000 in the Department of Pathology, Ahmadu Bello University Teaching Hospital [A.B.U.T.H], Zaria is presented.
  • Malignant tumours constituted 72.5%; benign tumours 18.3% and tumour-like lesions 9.2%.
  • The commonest malignant lesion was squamous cell carcinoma, which constituted 68.3% of all the lesions with a male to female ratio of 1.7:1.
  • CONCLUSION: It is concluded that epidermal tumours and tumour-like lesions are not uncommon in Zaria and they show a male preponderance with squamous cell carcinoma being the commonest epidermal tumour and it also predominantly affects males.
  • [MeSH-minor] Age Distribution. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Epidermal Cyst / epidemiology. Female. Hospitals, Teaching. Humans. Keratoacanthoma / epidemiology. Keratosis, Seborrheic / epidemiology. Male. Nigeria / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203131.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


9. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours.
  • Archival formalin-fixed, paraffin-embedded sections of 40 benign and 57 malignant salivary gland tumours were retrieved and retrospectively studied immunohistochemically using a polyclonal C-KIT antibody in an Envision/HRP technique.
  • In addition five samples of chronic submandibular sialadenitis, five normal minor salivary glands and parotid or submandibular gland tissue adjacent to benign tumour were also studied.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


10. Kuźbicki L, Gajo B, Chwirot BW: Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res; 2006 Jun;16(3):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
  • It is thought that enhanced expression of lysosome-associated membrane protein-1 in tumour cells may promote invasion by influencing both adhesion to extracellular matrix and perhaps also binding to endothelial cells.
  • The present study was aimed at examining levels of lysosome-associated membrane protein-1 in human melanomas and benign pigmented lesions to evaluate whether this protein might be considered a potential molecular marker of melanoma progression.
  • The expression of lysosome-associated membrane protein-1 was for the first time determined immunohistochemically in formalin-fixed paraffin-embedded specimens comprising 42 primary cutaneous melanomas, 15 lymph node melanoma metastases (11 correlated with primary tumours), three melanoma recurrences (correlated with both primary and metastatic melanomas), 27 nevi and four epithelial tumours (two seborrhoeic keratoses and two basal cell carcinomas).
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718270.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lysosomal-Associated Membrane Protein 1
  •  go-up   go-down


11. Mhawech-Fauceglia P, Herrmann FR, Bshara W, Odunsi K, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R, Mhawech-Fauceglia P: Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol; 2007 Jun;60(6):694-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.
  • BACKGROUND: Friend leukaemia integration-1 (FLI-1) antibody is a useful marker for Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET) and vascular tumours.
  • However, it is also expressed in subsets of lymphoblastic lymphoma, Merkel cell carcinoma (MCC) and desmoplastic small round cell tumour (DSRCT).
  • AIM: To determine expression of FLI-1 in various benign and malignant neoplasms, by immunohistochemical analysis on 4323 tumours using multiple tumour microarrays, as well as on whole sections.
  • RESULTS: FLI-1 was expressed in 46/62 EWS/PNETs, 2/3 olfactory neuroblastomas, 7/102 small cell carcinomas of the lung, 10/34 MCCs, 1/14 rhabdomyosarcoma, 19/132 non-Hodgkin's lymphomas, 2/3 DSRCTs, and in 53/74 benign and malignant vascular tumours.
  • In addition, 27/508 squamous cell carcinomas, 19/837 adenocarcinomas, 10/400 urothelial bladder cancers, 1/40 basal cell carcinomas, 3/29 liposarcomas, 1/40 glioblastoma multiforme and 9/29 medullar carcinomas of the breast expressed FLI-1.
  • Finally, the sensitivity and specificity of FLI-1 to distinguish EWS/PNET from other small round cell tumours (SRCTs) were 74.2% and 91.6%, respectively.
  • This finding should be kept in mind, especially when using FLI-1 as a marker for finding the primary origin of poorly differentiated metastatic tumour.
  • Finally, despite the expression of FLI-1 in numerous malignancies, it is still considered to be highly sensitive and specific in distinguishing EWS/PNET from other tumour types in general and from other SRCTs in particular.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Proto-Oncogene Protein c-fli-1 / metabolism
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / metabolism. Protein Array Analysis / methods. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / metabolism. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1657-62 [11117787.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mod Pathol. 2004 May;17(5):547-52 [15001993.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Int J Dev Biol. 1998 May;42(4):561-72 [9694627.001]
  • [Cites] Histopathology. 2005 Jun;46(6):622-34 [15910593.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1184-93 [16096408.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):151-4 [16633064.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):216-24 [10968707.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • (PMID = 16917000.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Protein c-fli-1
  • [Other-IDs] NLM/ PMC1955051
  •  go-up   go-down


12. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A: Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol; 2006 Feb;19(2):307-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
  • NGFR is reported to act as a tumour suppressor, negatively regulating cell growth and proliferation.
  • NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype.
  • Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR.
  • Positivity for NGFR was observed in 11 out of 245 (4.5%) breast carcinomas, nine out of 20 (45%) metaplastic breast carcinomas and 14 out of 37 (38%) basal-like breast carcinomas.
  • NGFR showed a statistically significant association with longer disease-free (P<0.05) and overall survival (P<0.01) in the cohort of patients with basal-like carcinomas.
  • Furthermore, provisional data in a small number of basal-like breast carcinomas suggest that NGFR may identify a subgroup of basal-like breast carcinomas with good prognosis.
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Keratin-14. Keratin-5. Keratin-6. Keratins / analysis. Myoepithelioma / metabolism. Myoepithelioma / pathology. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Nerve Growth Factor. Receptors, Progesterone / analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424897.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
  •  go-up   go-down


13. Gil da Costa RM, Rema A, Pires MA, Gärtner F: Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein. Vet Dermatol; 2010 Apr;21(2):198-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein.
  • Canine Merkel cell tumours are rare neuroendocrine neoplasms that show a relatively benign biological behaviour when compared with their human counterparts.
  • In both lesions, tumour cells were positive for cytokeratins, CGA, NSE, S100 and c-KIT.
  • These results suggest that the generally benign behaviour of canine Merkel cell tumours, when compared with their human counterparts, may be partly explained by the conservation of important intercellular adhesion molecules such as E-cadherin and beta-catenin.
  • Additionally, expression of S100 but not of the p63 protein suggests that these canine tumours present a trend towards neural, rather than basal, epithelial differentiation and do not readily compare with human Merkel cell tumours.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Merkel Cell / metabolism. Dog Diseases / diagnosis. Proto-Oncogene Proteins c-kit / metabolism. S100 Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Dogs. Female. Gene Expression Regulation, Neoplastic / physiology. Male

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706008.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / S100 Proteins; 0 / beta Catenin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


14. Chakraborty S, Swanson BJ, Bonthu N, Batra SK: Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. J Clin Pathol; 2010 Jul;63(7):579-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.
  • METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to human MUC4 (clone 8G7).
  • RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age.
  • Malignant melanoma, basal cell carcinoma and cutaneous cysts were negative.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Int J Gynecol Pathol. 2009 Mar;28(2):127-33 [19188823.001]
  • [Cites] Dermatol Clin. 2000 Apr;18(2):xv-xxi [10791144.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Microbes Infect. 2002 Sep;4(11):1121-4 [12361911.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Histopathology. 1984 May;8(3):423-34 [6329942.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):381-9 [16534686.001]
  • [Cites] J Dermatol. 2006 May;33(5):309-18 [16700662.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):556-62 [17425384.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):520-6 [18665193.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):949-56 [18781152.001]
  • [Cites] J Biosci. 2009 Mar;34(1):113-23 [19430123.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jan;41(1):82-8 [10634605.001]
  • (PMID = 20591909.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / R01 CA78590; United States / NCI NIH HHS / CA / P50 CA127297; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / R01 CA 133774; United States / NCI NIH HHS / CA / R01 CA133774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS224552; NLM/ PMC2920126
  •  go-up   go-down


15. Di Blasi A, Ferrara G, Antinolfi G, Dalena AM, Antinolfi F: [Clear cell adenomyoepithelioma of the ceruminous gland]. Pathologica; 2008 Jun;100(3):192-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell adenomyoepithelioma of the ceruminous gland].
  • We describe a case of a ceruminous tumour with complex morphology characterised by fibrous hyaline stroma bilayered epithelial ductal structures and nodules of tightly arranged clear cells with abundant Pas-positive cytoplasm.
  • Epithelial ductal basal cells were reactive for CK5, p63, calponin and SMA.
  • The lesion appears morphologically benign.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841827.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Cheah PL, Looi LM: Significance of Bcl-2 and Bax proteins in cervical carcinogenesis: an immunohistochemical study in squamous cell carcinoma and squamous intraepithelial lesions. Malays J Pathol; 2006 Jun;28(1):1-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of Bcl-2 and Bax proteins in cervical carcinogenesis: an immunohistochemical study in squamous cell carcinoma and squamous intraepithelial lesions.
  • Sixteen low grade (LSIL), 22 high grade (HSIL) squamous intraepithelial lesions, 28 invasive (13 stage I and 15 stage II-IV) squamous cell carcinoma (SCC) and 15 benign cervices were immunohistochemically studied for involvement of Bcl-2 and Bax proteins in cervical carcinogenesis.
  • Bcl-2 was upregulated (p < 0.05) in HSIL and Bax in SCC when compared with benign cervical squamous epithelium.
  • Bcl-2 expression was confined to the lower third of the epithelium in the benign cervices and LSIL.
  • SCCs showed "diffuse" (evenly distributed) or "basal" (intensified staining around the periphery of the invading tumour nests) expression of Bcl-2.
  • Of the 5 SCCs with upregulated Bcl-2, 1 of 2 (50%) stage I and 3 (100%) stage II-IV tumours exhibited the "basal" pattern.
  • Benign cervical squamous epithelium, LSIL, HSIL and SCC showed a generally diffuse Bax expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Uterine Cervical Neoplasms / metabolism. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694953.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


17. Tamiolakis D, Proimos E, Perogamvrakis GE, Skoulakis CE, Georgiou GC, Papadakis CE: Brushing cytology in cutaneous lesions of the head and neck. J Laryngol Otol; 2007 Jul;121(7):676-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aim was to evaluate its reliability in ulcerative and tumour-like conditions arising in the skin of the head and neck.
  • RESULTS: Cytological analysis identified 63 out of 64 histologically documented malignant tumours (60 primary basal cell and squamous cell carcinomas and three metastatic adenocarcinomas), and 21 out of 22 benign lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403275.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Heal C, Buettner P, Raasch B, Browning S: Minor skin excisions in general practice in North Queensland. Aust Fam Physician; 2006 Oct;35(10):825-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We excised more squamous cell carcinomas than basal cell carcinomas (0.74:1).
  • Our number needed to treat (benign or dysplastic naevi excised per melanoma) was 8.4.
  • Mean age for excision of melanoma, basal cell carcinoma and squamous cell carcinoma was 55, 60.9 and 63.8 years respectively.
  • Relative tumour density was greatest in the face, scalp and neck region for all skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Family Practice. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019461.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


19. Wang D, Chen S, Feng Y, Yang Q, Campbell BH, Tang X, Campbell WB: Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. Tumour Biol; 2006;27(5):261-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we report a significant reduction of 15-lipoxygenase 2 (15-LOX-2) in seven carcinoma cell lines of the human head and neck when compared with normal primary cultured keratinocytes, and 18 primary head and neck squamous cell carcinomas (HNSCC) when compared with matched normal mucosa.
  • 15-LOX-2 is mainly expressed in the mature cells of the benign squamous epithelium, but not in the basal layer cells of benign epithelium, suggesting a role of 15-LOX-2 in cell differentiation.
  • When the effects of NSAIDs were examined on cell proliferation and regulation of 15-LOX-2 in the carcinoma cells, NS398 treatment resulted in significant growth inhibition associated with upregulation of 15-LOX-2 and its major metabolite 15-S-HETE.
  • Finally, restoration of 15-LOX-2 expression into these carcinoma cells significantly inhibited cell proliferation.
  • [MeSH-minor] Carcinoma, Squamous Cell. Cell Proliferation. Cells, Cultured. Gene Expression Regulation, Enzymologic. Humans. Keratinocytes / enzymology. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16874012.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-37981
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.13.11.33 / ALOX15B protein, human; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase
  •  go-up   go-down


20. Demirseren ME, Afandiyev K, Ceran C: Reconstruction of the perioral and perinasal defects with facial artery perforator flaps. J Plast Reconstr Aesthet Surg; 2009 Dec;62(12):1616-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve clinical cases with 14 perioral and perinasal skin defects resulting from malignant or benign skin tumour excision were reconstructed using facial artery perforator flaps.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Esthetics. Face / blood supply. Female. Humans. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / surgery. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010102.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


21. De Melo MR Jr, Araújo Filho JL, Patu VJ, Machado MC, Mello LA, Carvalho LB Jr: Langerhans cells in cutaneous tumours: immunohistochemistry study using a computer image analysis system. J Mol Histol; 2006 Nov;37(8-9):321-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry, based on antibody anti-S100 protein, was used to evaluate the Langerhans cells (LC) in benign and malign skin neoplasias.
  • These cells were quantitatively estimated using a computer image analysis (OPTIMAS software system, Version 6.1) in skin biopsies diagnosed as basal cell carcinoma (BCC), epidermoid carcinoma (EpC), trichoepithelioma (TE), keratoacanthoma (KA), seborreic keratosis (SK) and actinic keratosis (AK).
  • No significant variations were observed in the number of LC among malignant tumour (BCC = 23.25 +/- 5.81 and EpC = 20.88 +/- 4.24).
  • Benign lesions (AK = 33.04 +/- 7.11; TE = 55.74 +/- 9.35; SK = 42.38 +/- 9.92, and KA = 47.62 +/- 10.4) presented a higher number of LC when they were compared among them and to malignant and normal tissues.
  • No significant differences were observed in LC area and volume between benign and malign neoplasias.
  • These results indicate possibly differences in the immunogenicity between benign and malign epidermic tumours.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Image Processing, Computer-Assisted / methods. Immunohistochemistry / methods. Langerhans Cells / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080294.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Yerli H, Aydin E, Haberal N, Harman A, Kaskati T, Alibek S: Diagnosing common parotid tumours with magnetic resonance imaging including diffusion-weighted imaging vs fine-needle aspiration cytology: a comparative study. Dentomaxillofac Radiol; 2010 Sep;39(6):349-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: masses comprised eight Warthin tumours, eight adenomas (six pleomorphic adenomas, two basal cell adenomas), five carcinomas, two lipomas, one haemagioma and one benign lymphadenopathy.
  • Diagnostic accuracy did not increase by adding DWI to conventional MRI; however, DWI was helpful for diagnosing benign tumour histology.
  • MRI combined with DWI was successful for determining accurate tumour typing in all benign masses except one lymphadenopathy.
  • CONCLUSIONS: MRI combined with DWI seems to have similar diagnostic potential as FNAC in differentiation of benign vs malignant parotid masses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1999 Nov;35(5):432-8 [10583558.001]
  • [Cites] Radiology. 2000 Jul;216(1):19-29 [10887223.001]
  • [Cites] Radiology. 2001 Sep;220(3):621-30 [11526259.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1989-92 [11801984.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):959-65 [11906883.001]
  • [Cites] Clin Radiol. 2002 Aug;57(8):692-701 [12169280.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Aug;25(7):1256-62 [15313720.001]
  • [Cites] Radiology. 1989 Dec;173(3):823-6 [2813793.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17(3):555-9 [8881252.001]
  • [Cites] Head Neck. 1999 Jan;21(1):43-51 [9890350.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1201-6 [15891184.001]
  • [Cites] Ann Acad Med Singapore. 2006 Apr;35(4):242-8 [16710494.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jan;28(1):116-21 [17213436.001]
  • [Cites] Acad Radiol. 2007 Jun;14(6):701-10 [17502260.001]
  • [Cites] Acta Radiol. 2007 Nov;48(9):980-7 [17957512.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Mar;30(3):591-6 [19131405.001]
  • (PMID = 20729184.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3520240
  •  go-up   go-down


23. Persichetti P, Langella M, Cogliandro A, Marangi GF, Perrella E, Rabitti C, Mellone P, Baldi A: Cutaneous lymphoadenoma: a rare clinicopathological entity. J Exp Clin Cancer Res; 2005 Sep;24(3):497-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous Lymphadenoma (Benign Lymphoepithelial tumour of the skin) is a rare tumour, with distinctive clinical and histological features.
  • We present a case of cutaneous lymphoadenoma in a 52-year-old man and a short review of the literature, summarizing the principal clinical and morphological characteristics of this rare tumour.
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270539.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


24. Bugatti L, Filosa G: Dermatoscopic features of cutaneous atypical fibroxanthoma: three cases. Clin Exp Dermatol; 2009 Dec;34(8):e898-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical fibroxanthoma (AFX) is an uncommon, low-grade, malignant, spindle-cell tumour of fibrohistiocytic histogenesis, which can mimic other malignant skin tumours, such as basal and squamous cell carcinoma (CC), melanoma, and Merkel cell carcinoma (MCC).
  • [MeSH-major] Dermoscopy / methods. Histiocytoma, Benign Fibrous / pathology. Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055861.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Driemel O, Maier H, Kraft K, Haase S, Hemmer J: Flow cytometric DNA ploidy in salivary gland tumours. Oncol Rep; 2005 Jan;13(1):161-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study on 279 tumours of the salivary glands was conducted to analyse whether the assessment of DNA ploidy by flow cytometry may assist histopathology in discriminating benign from malignant types of tumours.
  • The group of benign tumours included 164 pleomorphic adenomas, 51 Warthin's tumours, 7 basal cell adenomas, 2 lipomas as well as 5 other different tumours.
  • All of the 229 benign tumours were diploid.
  • The malignant tumours consisted of 18 adenoid cystic adenomas, 10 mucoepidermoid carcinomas, 5 acinic cell carcinomas, 5 carcinoma in pleomorphic adenoma as well as of 12 other malignancies belonging to 7 different tumour entities.
  • In three cases which initially were taken for pleomorphic adenomas by routine histological examination, aneuploid cell populations exposed by DNA flow cytometric analysis gave rise to a closer inspection of the suspect lesions.
  • [MeSH-major] DNA, Neoplasm / analysis. Flow Cytometry. Ploidies. Salivary Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583819.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


26. Biswas D, Saha S, Bera SP: Relative distribution of the tumours of ear, nose and throat in the paediatric patients. Int J Pediatr Otorhinolaryngol; 2007 May;71(5):801-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients 15 years of age or under who presented with a tumour of the otolaryngological region to the department of Otolaryngology were included in this study.
  • RESULTS: Forty-three patients of above age group with a neoplasm of the otolaryngological region were managed in our department, the incidence was 0.5%.
  • The ratio of benign to malignant lesion was 7.6:1.
  • Juvenile nasopharyngeal angiofibroma was the commonest tumour (11 cases, 26%) and embryonal rhabdomyosarcoma was the commonest malignant tumour (3 cases, 7%).
  • The commonest site of neoplasm was the nose and paranasal sinuses (13 cases, 30%).
  • CONCLUSION: A tumour in the otolaryngological site in the paediatric population is rare, the incidence being 1 in 200 new cases in the age group of 15 years or under, 12% of the tumours were malignant.
  • [MeSH-minor] Adolescent. Carcinoma, Basal Cell / epidemiology. Child. Child, Preschool. Female. Hemangioma / epidemiology. Humans. Incidence. Infant. Male. Papilloma / epidemiology. Prevalence. Prospective Studies. Rhabdomyosarcoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368816.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


27. Rentsch CA, Cecchini MG, Schwaninger R, Germann M, Markwalder R, Heller M, van der Pluijm G, Thalmann GN, Wetterwald A: Differential expression of TGFbeta-stimulated clone 22 in normal prostate and prostate cancer. Int J Cancer; 2006 Feb 15;118(4):899-906
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Verification of their mRNA expression by real-time PCR in patient-matched NP and PC bulk tissue, in laser-captured pure epithelial and cancer cells and in NP and PC cell lines confirmed TSC-22 underexpression, but not Id4 overexpression, in PC and in human PC cell lines.
  • Immunohistochemical analysis showed that TSC-22 protein expression in NP is restricted to the basal cells and colocalizes with the basal cell marker cytokeratin 5.
  • Likewise, PC cell lines do not show detectable TSC-22 protein expression as shown by immunoblotting.
  • TSC-22 should be considered as a novel basal cell marker, potentially useful for studying lineage determination within the epithelial compartment of the prostate.
  • Accordingly, TSC-22 immunohistochemistry may prove to be a diagnostic tool for discriminating benign lesions from malignant ones of the prostate.
  • The suggested tumour suppressor function of TSC-22 warrants further investigation on its role in prostate carcinogenesis and on the TSC-22 pathway as a candidate therapeutic target in PC.
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. RNA, Messenger / biosynthesis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106424.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / TSC22D1 protein, human; 0 / Transforming Growth Factor beta
  •  go-up   go-down


28. Kim JE, Kim HJ, Choi JM, Lee KH, Kim TY, Cho BK, Jung JY, Chung KY, Cho D, Park HJ: The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol; 2010 Nov;163(5):959-67
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Human cationic antimicrobial protein-18 (hCAP-18)/LL-37 production in several cell lines including HaCaT, a chronic myelogenous leukaemia (CML) cell line and various melanoma cell lines was examined using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay.
  • Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed.
  • After adding LL-37 to a melanoma cell line, tumour cell proliferation, migration and invasion were investigated.
  • RESULTS: Human malignant melanoma cell lines overexpressed hCAP-18/LL-37 mRNA and peptide compared with HaCaT and CML cell lines.
  • Immunohistochemistry showed that the peptide was strongly expressed in malignant melanoma and moderately expressed in squamous cell carcinoma, whereas basal cell carcinoma, precancerous lesions and seborrhoeic keratosis showed no or weak expression.
  • LL-37 also stimulated melanoma cell proliferation, migration and invasion in vitro.
  • LL-37 promoted melanoma cell proliferation, migration and invasion in vitro.
  • [MeSH-major] Antimicrobial Cationic Peptides / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor / metabolism. Cell Movement / physiology. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Precancerous Conditions / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20977442.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 143108-26-3 / CAP18 lipopolysaccharide-binding protein
  •  go-up   go-down


29. Kamat G, Yelikar B, Shettar S, Karigoudar MH: Pigmented trichoblastoma with sebaceous hyperplasia. Indian J Dermatol Venereol Leprol; 2009 Sep-Oct;75(5):506-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trichoblastoma is a rare benign trichogenic tumour with epithelial and mesenchymal components recapitulating the germinal hair bulb and associated mesenchyme.
  • Microscopy of tumour revealed nodular tumour spanning the entire dermis with collection of mesenchymal cells resembling follicular papilla.
  • There is a need for differentiation of this tumor which is benign, from other pigmented tumors having basaloid arrangement of cells such as basal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736433.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


30. Golod O, Soriano T, Craft N: Palisaded encapsulated neuroma--a classic presentation of a commonly misdiagnosed neural tumor. J Drugs Dermatol; 2005 Jan-Feb;4(1):92-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palisaded encapsulated neuroma--a classic presentation of a commonly misdiagnosed neural tumor.
  • PEN is a previously described, benign cutaneous neural tumour, with a histological appearance between that of a neurofibroma and a schwannoma.
  • Clinically, PEN is most commonly misdiagnosed as a basal cell carcinoma, a nevus, or as a neurofibroma.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696992.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


31. Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J: Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien); 2005 Jul;147(7):751-7; discussion 757-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prolactinomas usually exhibit a benign course and can be safely and effectively managed by dopamine agonists (DA).
  • The aim of the present study was to determine whether histological features and markers of cell proliferation correlated to the clinical behaviour of prolactinomas and with DA resistance.
  • The prolactinomas were categorized on the basis of tumour size (48 macroadenomas), invasion of the cavernous sinus (n = 31), and resistance to bromocriptine (BRC) therapy (n = 14).
  • Seven additional parameters were studied, these being age, sex, basal prolactin (PRL) levels, the Ki-67 and PCNA labelling indices (LI), mitotic count, and cellular atypia.
  • Tumour size and invasion were related to cellular atypia and the Ki-67 LI.
  • These findings justify the long-term follow up of these tumours, and the use of surgery and/or radiotherapy if there is concern about the control of tumour growth.
  • [MeSH-minor] Adult. Aged. Drug Resistance. Female. Humans. Hypophysectomy. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pituitary Gland / pathology. Retrospective Studies. Sex Factors

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15971099.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ki-67 Antigen; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


32. Alsaad KO, Obaidat NA, Ghazarian D: Skin adnexal neoplasms--part 1: an approach to tumours of the pilosebaceous unit. J Clin Pathol; 2007 Feb;60(2):129-44
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin adnexal neoplasms comprise a wide spectrum of benign and malignant tumours that exhibit morphological differentiation towards one or more types of adnexal structures found in normal skin.
  • In this review, the first of two, the normal histology of the skin adnexal structures is reviewed, and the histological features of selected but important benign and malignant tumours and tumour-like lesions of pilosebaceous origin discussed, with emphasis on the diagnostic approach and pitfalls in histological diagnosis.
  • [MeSH-minor] Humans. Neoplasms, Basal Cell / pathology. Sebaceous Gland Neoplasms / pathology. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Derm Venereol. 1995 May;75(3):187-9 [7653177.001]
  • [Cites] Int J Dermatol. 1995 Nov;34(11):782-5 [8543411.001]
  • [Cites] J Cutan Pathol. 1995 Oct;22(5):422-6 [8594074.001]
  • [Cites] J Invest Dermatol. 1996 Jul;107(1):41-3 [8752837.001]
  • [Cites] Am J Dermatopathol. 1996 Apr;18(2):218-9 [8740001.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):296-301 [8806965.001]
  • [Cites] J Dermatol. 1996 Nov;23(11):821-4 [8990706.001]
  • [Cites] Br J Dermatol. 1997 Jan;136(1):30-4 [9039291.001]
  • [Cites] APMIS. 1997 Jan;105(1):35-40 [9063499.001]
  • [Cites] Am J Dermatopathol. 1998 Apr;20(2):140-2 [9557781.001]
  • [Cites] Lupus. 1998;7(3):207-9 [9607646.001]
  • [Cites] Pathology. 1998 May;30(2):212-4 [9643508.001]
  • [Cites] J Cutan Pathol. 1998 Sep;25(8):435-9 [9826169.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):8-15 [10027518.001]
  • [Cites] Br J Dermatol. 1999 Jan;140(1):8-16 [10215762.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Oct;81(5):536-8 [14510806.001]
  • [Cites] Eur J Dermatol. 2003 Sep-Oct;13(5):487-9 [14693496.001]
  • [Cites] J Cutan Pathol. 2004 Apr;31(4):330-5 [15005691.001]
  • [Cites] Hum Mutat. 2004 Apr;23(4):400 [15024746.001]
  • [Cites] J Invest Dermatol. 2004 Mar;122(3):658-64 [15086550.001]
  • [Cites] Am J Dermatopathol. 2004 Aug;26(4):298-303 [15249860.001]
  • [Cites] Semin Cutan Med Surg. 2004 Jun;23(2):145-57 [15295924.001]
  • [Cites] J Cutan Pathol. 2005 Aug;32(7):491-5 [16008693.001]
  • [Cites] J Cutan Pathol. 2005 Aug;32(7):496-501 [16008694.001]
  • [Cites] Int J Dermatol. 2005 Aug;44(8):668-73 [16101870.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):68-70 [16309487.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):980-7 [16321766.001]
  • [Cites] J Dermatol Sci. 2006 Jan;41(1):67-75 [16378715.001]
  • [Cites] J Cutan Pathol. 2006 Feb;33(2):123-8 [16420307.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1834-6 [10213487.001]
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):426-31 [10535570.001]
  • [Cites] Dermatology. 1999;199(4):338-40 [10640845.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):263-8 [10642683.001]
  • [Cites] Am J Dermatopathol. 2000 Apr;22(2):108-18 [10770429.001]
  • [Cites] Am J Dermatopathol. 2000 Apr;22(2):183-7 [10770443.001]
  • [Cites] Eur J Dermatol. 1999 Jul-Aug;9(5):363-5 [10417438.001]
  • [Cites] Br J Plast Surg. 1999 Mar;52(2):143-5 [10434894.001]
  • [Cites] Am J Dermatopathol. 1999 Aug;21(4):332-6 [10446773.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):433-7 [10448295.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 2):1546-9 [15606837.001]
  • [Cites] J Dermatol. 2004 Oct;31(10):824-7 [15672712.001]
  • [Cites] Am J Dermatopathol. 2005 Feb;27(1):9-16 [15677970.001]
  • [Cites] J Dermatol. 2004 Dec;31(12):998-1008 [15801265.001]
  • [Cites] Clin Exp Dermatol. 2005 May;30(3):259-60 [15807685.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):189-206 [10906638.001]
  • [Cites] Am J Dermatopathol. 2000 Aug;22(4):311-5 [10949455.001]
  • [Cites] Malays J Pathol. 1999 Dec;21(2):117-21 [11068417.001]
  • [Cites] Ann Dermatol Venereol. 2001 Jan;128(1):35-7 [11226898.001]
  • [Cites] Am J Dermatopathol. 2001 Apr;23(2):90-8 [11285402.001]
  • [Cites] J Am Acad Dermatol. 2001 Dec;45(6):886-91 [11712034.001]
  • [Cites] Pathologe. 2002 Jan;23(1):71-8 [11974506.001]
  • [Cites] Am J Dermatopathol. 2002 Apr;24(2):149-55 [11979076.001]
  • [Cites] Am J Dermatopathol. 2002 Aug;24(4):294-304 [12142607.001]
  • [Cites] Dermatol Surg. 2003 Jan;29(1):105-7 [12534523.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):453-5 [12637930.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):130-7 [12652194.001]
  • [Cites] Dermatology. 2003;207(1):57-60 [12835551.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):886-9 [12859397.001]
  • [Cites] J Cutan Pathol. 2003 Sep;30(8):492-8 [12950500.001]
  • [Cites] J Cutan Pathol. 2003 Sep;30(8):499-503 [12950501.001]
  • [Cites] J Cutan Pathol. 2000 Apr;27(4):169-75 [10774937.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):673-8 [10874673.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Sep;18(5):607-10 [15324407.001]
  • [Cites] Arch Dermatol. 1979 Aug;115(8):1003-4 [464613.001]
  • [Cites] Br J Dermatol. 1979 Jun;100(6):667-73 [465314.001]
  • [Cites] J Cutan Pathol. 1980 Dec;7(6):394-403 [7451702.001]
  • [Cites] Arch Dermatol. 1980 Dec;116(12):1395 [7458368.001]
  • [Cites] Arch Pathol Lab Med. 1984 Oct;108(10):808-10 [6548121.001]
  • [Cites] Arch Dermatol. 1985 Mar;121(3):413-5 [2983619.001]
  • [Cites] Am J Dermatopathol. 1985 Jun;7(3):207-21 [4051130.001]
  • [Cites] J Am Acad Dermatol. 1989 Apr;20(4):537-63 [2654204.001]
  • [Cites] J Cutan Pathol. 1990 Feb;17(1):45-52 [2319039.001]
  • [Cites] Am J Dermatopathol. 1991 Jun;13(3):275-81 [1867358.001]
  • [Cites] Am J Dermatopathol. 1992 Apr;14(2):107-4 [1373583.001]
  • [Cites] Am J Dermatopathol. 1994 Feb;16(1):23-30 [8160927.001]
  • [Cites] Arch Dermatol. 1994 May;130(5):589-92 [7513986.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):985-6 [8064466.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):198-201 [7857118.001]
  • [Cites] Arch Dermatol. 1995 Apr;131(4):454-8 [7726589.001]
  • (PMID = 16882696.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  • [Other-IDs] NLM/ PMC1860623
  •  go-up   go-down


33. Conscience I, Jovenin N, Coissard C, Lorenzato M, Durlach A, Grange F, Birembaut P, Clavel C, Bernard P: P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol; 2006 Sep-Oct;16(5):518-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recently, an increased expression of P16, a cell cycle regulatory tumor suppressor protein, has been demonstrated in cervical squamous neoplasms as a marker of malignancy.
  • OBJECTIVES: Our first aim was to evaluate P16 expression in different types of non-melanoma skin cancers compared with normal skin and benign tumors.
  • METHODS: Skin biopsy specimens with typical histologic features of squamous cell carcinoma (SCC; n = 30), Bowen's disease (BD; n = 17), basal cell carcinoma (BCC; n = 10), seborrheic keratosis (SK; n = 10) and normal human skin (NHS; n = 9) were obtained from 76 patients seen at our institution between 2001 and 2003.
  • Ki67 expression in over 5% of tumour cells was observed in 69% of cutaneous carcinomas (SCC: 54%; BD: 76%; BCC: 80%) versus 16% in the group including SK (30%) and NHS (0%) (p = 0.04).
  • Overexpression of P16 was associated with a high rate of Ki67 positive tumour cells in 23/57 malignant skin tumors (40%).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101472.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


34. Kroll J, Busse H: [Tumours of the lacrimal passages]. Klin Monbl Augenheilkd; 2008 Jan;225(1):91-5
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We evaluated retrospectively the files of all patients with tumours in the lacrimal drainage system of the university eye clinic in Münster between 1992 and 2002 considering the dignity and type of tumour, the localisation, the symptoms, operation and the anaesthetic procedure.
  • RESULTS: We could find 75 patients with tumours in the lacrimal drainage system, out of which 40 were benign, 25 semi-malignant and 10 malignant tumours.
  • Among the benign tumours were 15 nevus cell nevi, 7 granulation tissue tumours, 5 papillomas, 4 cysts, 1 fibroma, 1 sebborrhoic keratosis, 1 adenoma of secretory duct, 2 inflamed pseudotumours and 2 benign tumours without histopathologic findings.
  • The semi-malignant tumours were exclusively basal cell carcinomas.
  • In that site, most of the tumours were of benign or semi-malignant origin.
  • One should be aware of the fact that this symptom can always be masqueraded by a tumour.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236378.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Yao D, Alexander CL, Quinn JA, Chan WC, Wu H, Greenhalgh DA: Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J Cell Sci; 2008 May 15;121(Pt 10):1758-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A pivotal facet to this GSK3beta-triggered mechanism centred on increasing p53 expression in basal layer keratinocytes.
  • This increase in expression reduced activated AKT expression and released inhibition of p21 WAF, which accelerated keratinocyte differentiation, as indicated by unique basal layer expression of differentiation-specific keratin K1 alongside premature filaggrin and loricrin expression.
  • Thus, Fos synergism with Pten loss elicited a benign tumour context where GSK3beta-induced p53/p21 WAF expression continually switched AKT-associated proliferation into differentiation, preventing further progression.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Keratinocytes / metabolism. Keratoacanthoma / metabolism. Oncogene Proteins v-fos / metabolism. PTEN Phosphohydrolase / metabolism. Tumor Suppressor Protein p53 / metabolism


36. Antony FC, Sanclemente G, Shaikh H, Trelles AS, Calonje E: Pigment synthesizing melanoma (so-called animal type melanoma): a clinicopathological study of 14 cases of a poorly known distinctive variant of melanoma. Histopathology; 2006 May;48(6):754-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical diagnosis was of melanoma in seven cases, blue naevus in three cases, benign naevus in three cases and a pigmented basal cell carcinoma in one case.
  • The histological diagnosis of PSM was predicated on the basis of an asymmetrical, predominantly intradermal tumour formed of deeply pigmented, round or short, spindle-shaped dendritic melanocytes with some degree of hyperchromatism and a single nucleolus.
  • [MeSH-minor] Adolescent. Adult. Antigens, Neoplasm. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanocytes / chemistry. Melanocytes / pathology. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local. Nevus, Blue / metabolism. Nevus, Blue / pathology. Nevus, Pigmented / metabolism. Nevus, Pigmented / pathology. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681693.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


37. Maitland NJ, Bryce SD, Stower MJ, Collins AT: Prostate cancer stem cells: a target for new therapies. Ernst Schering Found Symp Proc; 2006;(5):155-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most treatments are directed towards an androgen receptor-expressing, highly proliferative target cell, which does indeed form the vast majority of cells in a prostate tumour.
  • However, by invoking the existence of a cancer stem cell which, like normal epithelial stem cells in the prostate, does not express androgen receptor and is relatively quiescent, the observed resistance to most medical therapies can be explained.
  • The phenotype of the prostate cancer stem cells is that of a basal cell and cultures derived from cancers, but not benign tissues, express a range of prostate cancer-associated RNAs.
  • Furthermore, stem cells purified on the basis of alpha2beta1 high integrin and CD133 cell surface antigen expression, from an established culture of Gleason 4 (2+2) prostate cancer (P4E6), were able to form multiple intraprostatic tumours in nude mice when grafted orthotopically in a matrigel plug containing human prostatic stroma.
  • [MeSH-minor] Cell Separation. Gene Expression. Genetic Therapy. Humans. Immunotherapy. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939301.001).
  • [Journal-full-title] Ernst Schering Foundation symposium proceedings
  • [ISO-abbreviation] Ernst Schering Found Symp Proc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 68
  •  go-up   go-down


38. Ye WM, Zhu HG, Zheng JW, Wang XD, Zhao W, Zhong LP, Zhang ZY: Use of allogenic acellular dermal matrix in prevention of Frey's syndrome after parotidectomy. Br J Oral Maxillofac Surg; 2008 Dec;46(8):649-52
Genetic Alliance. consumer health - Frey's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: We studied a total of 168 patients with benign parotid gland tumours, including 89 patients with pleomorphic adenoma; 45 with Warthin tumour; 17 with basal cell adenoma; and 17 with miscellaneous tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547692.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Alloderm; 9007-34-5 / Collagen
  •  go-up   go-down


39. Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM, Vizoso FJ: Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer; 2010 Mar 2;102(5):922-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Extracellular matrix metalloproteases (MMPs) have raised an extraordinary interest in cancer research because of their potential role in basal membrane and extracellular matrix degradation, consequently facilitating tumour invasion and metastases development.
  • More than 2600 determinations on cancer specimens from 133 patients with clinically localised prostate carcinoma, 20 patients with prostatic intraepithelial neoplasia and 50 patients with benign prostate hyperplasia and controls, were performed.
  • RESULTS: When compared with benign pathologies, prostate carcinomas had higher expression of all MMPs and TIMPs.
  • CONCLUSION: The expression of MMPs and TIMPs seems to have an important role in the molecular biology of prostate carcinomas, and their expression by tumours may be of clinical interest to used as indicators of tumour aggressiveness.
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Follow-Up Studies. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 1999 Mar;24(2):122-6 [10233668.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):21-8 [15630412.001]
  • [Cites] Urol Res. 2005 Feb;33(1):44-50 [15517230.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1173-86 [15793297.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):770-8 [15841326.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):215-27 [15947098.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):673-84 [15976331.001]
  • [Cites] Prog Urol. 2005 Apr;15(2):250-4 [15999602.001]
  • [Cites] Crit Rev Immunol. 2005;25(6):493-523 [16390324.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):973-82 [16619495.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):903-11 [17342087.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):349-57 [17460779.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2100-11 [17525276.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):957-63 [17848954.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6232-40 [18174174.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):757-65 [18360703.001]
  • [Cites] Oncology. 2008;75(3-4):230-6 [18852494.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):118-21 [10756061.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):860-5 [10923925.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4823-30 [11156241.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):111-118 [11112695.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1022-8 [11221828.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2189-93 [11280785.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1076-83 [11308257.001]
  • [Cites] Neoplasia. 2001 Nov-Dec;3(6):459-68 [11774028.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):723-8 [12090420.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(1):15-26 [12664060.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):309-16 [12949813.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):217-22 [12970724.001]
  • [Cites] Clin Exp Metastasis. 2003;20(6):541-7 [14598888.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R24-30 [14680497.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1131-9 [15039201.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1187-92 [15138554.001]
  • [Cites] Cancer Cell. 2004 May;5(5):409-10 [15144947.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):699-704 [1701851.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):448-51 [8980245.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 May;26(1):43-53 [9246540.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):96-101 [9495366.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):721-8 [9502414.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6935-45 [10066747.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2004;7(4):327-32 [15356679.001]
  • (PMID = 20160732.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2833257
  •  go-up   go-down


40. Hussein MR, Elsers DA, Fadel SA, Omar AE: Clinicopathological features of melanocytic skin lesions in Egypt. Eur J Cancer Prev; 2006 Feb;15(1):64-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions examined included 12 benign naevi (BN), 10 dysplastic naevi (DN), and 21 cutaneous malignant melanomas (CMMs).
  • The mean tumour thickness (Breslow) was 6+/-0.5 mm.
  • In Egypt, CMM is the third most common cutaneous neoplasm following squamous and basal cell carcinomas.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374232.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement